HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing Loss

Project Information

Sense21

Grant agreement ID: 190142580

DOI 10.3030/190142580

Project closed

EC signature date 25 May 2022

Start date 1 June 2022

End date 31 May 2025

Funded under

• The European Innovation Council (EIC)

Total cost € 3 321 875,00

EU contribution € 2 325 312,50

Coordinated by

HOBA THERAPEUTICS APS
Denmark

Project description

Therapeutic proteins to treat nerve pain and hearing loss

Current treatments for nerve (neuropathic) pain do not sufficiently treat pain symptoms. Most have serious side effects. Existing treatment options for hearing aids and cochlear implants are limited, with no approved pharmaceutical therapies. The EU-funded Sense21 project proposes novel therapeutics called HB-086 and HB-097 to treat neuropathic pain and hearing disorders. Research shows these two molecules have unique actions on sensory nerve cells and their surrounding support cells. Preclinical data reveal that HB-086 provides relief from neuropathic pain, while HB 097 preserves the sense of hearing. They could serve as novel treatment approaches and bring about a radical change in medical treatment and in the prevention of severe chronic conditions.

Objective

HB-086 and HB-097 comprise our portfolio of therapeutic proteins. They are a family of growth factors with actions on sensory nerve cells and represent a novel treatment approaches and a paradigm shift for medical treatment and prevention of severe, chronic conditions as pain and hearing loss. The drug candidates target sensory nerve cells and their support cells in dorsal root ganglia and inner ear. Evidence indicate a mode of action including normalisation of impaired neuronal-glial crosstalk, protection, and regeneration of sensory nerve fibres. All key biological mechanisms underpinning increased peripheral afferent drive associated with chronic pain, and apoptotic hearing loss. Preclinical data confirm that HB-086 completely abolishes pain sensation across different models and HB-097 preserves the sense of hearing in relevant models. Importantly, documented prolonged effects warrant biweekly or monthly dosing and prevention of further disease progression.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• natural sciences › biological sciences › biochemistry › biomolecules › proteins

You need to log in or register to use this function

Keywords

• Health-related biotechnology
• Clinical medicine
• Neuropathic pain
• Hearing loss
• Sensory neuronal dysfunction

Programme(s)

• HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
• HORIZON.3.1.2 - The Accelerator

Topic(s)

• HORIZON-EIC-2021-ACCELERATOROPEN-01 - EIC Accelerator Open 2021

Call for proposal

HORIZON-EIC-2021-ACCELERATOROPEN-01

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Coordinator

HOBA THERAPEUTICS APS

• Net EU contribution: € 2 325 312,50
• Address: OLE MAALOES VEJ 3 ; 2200 Copenhagen ; Denmark
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  Danmark › Hovedstaden › Byen København
• Region: Danmark › Hovedstaden › Byen København
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 3 321 875,00